急性下肢深静脉血栓的血管内治疗:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项比较导管导向溶栓、药物机械溶栓和/或静脉支架与口服抗凝的研究,主要终点为血栓后综合征(PTS)发生率。结果显示导管导向溶栓降低PTS发生率(RR 0.56,95%CI 0.43-0.73),药物机械溶栓对PTS影响未达统计学显著(RR 0.87,95%CI 0.75-1.01);导管导向溶栓后复发VTE减少(RR 0.62,95%CI 0.34-1.13),但出血并发症增加(RR 5.11,95%CI 2.16-12.08)。
要点
- 导管导向溶栓可降低髂股DVT患者PTS发生率。
- 药物机械溶栓对PTS的降低未达统计学显著。
- 导管导向溶栓增加出血并发症风险,需权衡获益。
核心结论
- 导管导向溶栓治疗髂股DVT可降低PTS发生率,药物机械溶栓则不能。
- 导管导向溶栓减少复发VTE,但较口服抗凝增加出血并发症。
- 需进一步随机对照试验确定髂股水平以下DVT及静脉支架的血管内治疗作用。
研究设计与样本
- 系统综述与荟萃分析,纳入比较导管导向溶栓、药物机械溶栓和/或静脉支架与口服抗凝的研究。
- 最终纳入5项研究。
- 主要结局为PTS发生率,次要结局为复发VTE和出血并发症发生率。
- 治疗效应以风险比(RR)及其95%置信区间(CI)计算。
主要发现
- 导管导向溶栓降低PTS发生率(RR 0.56,95%CI 0.43-0.73)。
- 药物机械溶栓对PTS发生率影响较小且未达统计学显著(RR 0.87,95%CI 0.75-1.01)。
- 导管导向溶栓后复发VTE较口服抗凝减少(RR 0.62,95%CI 0.34-1.13)。
- 导管导向溶栓后出血并发症更常见(RR 5.11,95%CI 2.16-12.08)。
临床怎么用
- 对髂股DVT患者,可考虑导管导向溶栓以降低PTS和复发VTE风险。
- 选择导管导向溶栓时需评估出血风险,因出血并发症较口服抗凝明显增加。
- 药物机械溶栓在降低PTS方面证据未达统计学显著,决策需个体化。
局限性
- 仅纳入5项研究,证据基础有限。
- 髂股水平以下DVT及静脉支架的作用尚不明确,需进一步随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deep vein thrombosis (DVT) is associated with significant complications, including the development of post-thrombotic syndrome (PTS). Traditional management is with oral anticoagulation, but the endovascular techniques of catheter-directed thrombolysis (CDT), pharmacomechanical thrombolysis, and venous stenting are now increasingly used. This study aims to review the evidence for these endovascular techniques in the management of acute lower limb DVT, and their role in the reduction of complications such as PTS. METHODS: A systematic review and meta-analysis was carried out, with studies that compared CDT, pharmacomechanical thrombolysis, and/or venous stenting with oral anticoagulation included. Primary outcome measure was the incidence of PTS; secondary outcome measures were the incidence of recurrent venous thromboembolism (VTE) and bleeding complications. Treatment effects were calculated as risk ratios (RR) with their 95% confidence interval (CI). RESULTS: Five studies met the final inclusion criteria. CDT reduced the incidence of PTS (RR 0.56, 95% CI 0.43-0.73), whereas pharmacomechanical thrombolysis had only a minor effect on the incidence of PTS that did not achieve statistical significance (RR 0.87, 95% CI 0.75-1.01). Recurrent VTE following CDT was reduced compared to oral anticoagulation (RR 0.62, 95% CI 0.34-1.13), while bleeding complications were more likely following CDT (RR 5.11, 95% CI 2.16-12.08). CONCLUSIONS: CDT decreases the incidence of PTS when treating iliofemoral DVT, but pharmacomechanical thrombolysis does not. CDT also reduces the incidence of recurrent VTE, but leads to more bleeding complications when compared to oral anticoagulation. Further randomized controlled trials are needed to determine the role of endovascular management of DVT occurring below the iliofemoral level, and the role of venous stenting.
引用
- Thomas M, Hollingsworth A, Mofidi R, et al. Endovascular Management of Acute Lower Limb Deep Vein Thrombosis: A Systematic Review and Meta-analysis. Ann Vasc Surg. 2019. PMID: 30769054. doi:10.1016/j.avsg.2018.12.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。